氟康唑治疗NPTIIc(SLC34A3)突变患者一例报告
本文报告一例15岁男孩因肾钙质沉着症就诊,发现SLC34A3复合杂合突变,表现为高钙血症、高钙尿症、血磷正常、肾小管磷重吸收正常、1,25(OH)2D升高及PTH抑制。氢氯噻嗪未能降低尿钙,而氟康唑(1α-羟化酶抑制剂)有效使尿钙正常化且未降低GFR。作者提示SLC34A3突变可表现不典型,氟康唑效用需更大研究证实。
要点
- SLC34A3突变患者可表现血磷正常和肾小管磷重吸收正常的不典型表型。
- 1,25(OH)2D升高且CYP24A1无突变时,应考虑NPTIIc基因异常。
- 氟康唑可降低1,25(OH)2D并使尿钙正常化,但需更大研究确认。
核心结论
- SLC34A3突变可表现为血磷正常、肾小管磷重吸收正常的不典型表型;氟康唑可能通过抑制1α-羟化酶降低1,25(OH)2D并使尿钙正常化,但需更大研究确认。
研究设计与样本
- 个案报告:一例15岁男孩因肾钙质沉着症转诊,发现SLC34A3复合杂合突变。
主要发现
- 患者有高钙血症、高钙尿症、血磷正常、肾小管磷重吸收正常、血清1,25(OH)2D升高及PTH受抑制。
- 氢氯噻嗪未能降低尿钙。
- 氟康唑有效使尿钙正常化,且未降低肾小球滤过率。
临床怎么用
- 对1,25(OH)2D升高且CYP24A1无突变者,应考虑NPTIIc基因异常。
- SLC34A3突变患者可能血磷正常,需警惕不典型表现。
- 氟康唑降低1,25(OH)2D的作用需更大研究确认后方可常规应用。
局限性
- 仅为单例个案报告,结论需更大规模研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Mutations in the SLC34A3 gene, encoding the sodium/phosphate cotransporter 2C (NPTIIc), induce decreased renal phosphate reabsorption, hypophosphatemia, decreased fibroblast growth factor 23 and parathyroid hormone, and increased 1,25-dihydroxyvitamin D (1,25[OH]2D) levels. The complete phenotype is characterized by hypophosphatemia, hypercalciuria, and nephrolithiasis/nephrocalcinosis, leading to chronic kidney disease and osteoporosis in adults. We report a 15-year-old boy referred for nephrocalcinosis. The patient demonstrated hypercalcemia, hypercalciuria, normal serum phosphate level, normal tubular phosphate reabsorption, and increased serum 1,25(OH)2D level with suppressed serum parathyroid hormone. Compound heterozygous mutations in SLC34A3 were found. Hydrochlorothiazide failed to decrease calciuria. Fluconazole, an inhibitor of 1α-hydroxylase, was effective in normalizing calciuria without decreasing glomerular filtration rate. We conclude that children with SLC334A3 mutations can present with a less-typical phenotype, having normal serum phosphate levels and normal renal phosphate reabsorption. Genetic abnormalities of NPTIIc should be considered in cases of increased 1,25(OH)2D levels without mutations in CYP24A1. The utility of fluconazole to decrease 1,25(OH)2D levels requires confirmation in larger studies.
引用
- Bertholet-Thomas A, Tram N, Dubourg L, et al. Fluconazole as a New Therapeutic Tool to Manage Patients With NPTIIc (SLC34A3) Mutation: A Case Report. Am J Kidney Dis. 2019. PMID: 30765103. doi:10.1053/j.ajkd.2018.12.026
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。